Stefan Quenneville

Echelon Capital Markets

Recent Articles about Antibe Therapeutics Inc.

Biotech Co. Remains Opportunity for Those With High Risk Tolerance 06/30/2023

Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note.